Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.00
Bid: 16.50
Ask: 17.50
Change: -0.50 (-2.86%)
Spread: 1.00 (6.061%)
Open: 17.50
High: 17.50
Low: 17.00
Prev. Close: 17.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: STV raises holding in Two Cities Television

Wed, 31st Jan 2024 18:28

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Ethernity Networks Ltd - Israel-based supplier of data processing semiconductor technology for networking appliances - Announces the formal conclusion of the temporary suspension of proceedings process. Anticipates that the court will submit its formal approval of the settlement proposal during the first two weeks of February. Notwithstanding this, it is not considered necessary to seek a further extension to the TSP. Chief Executive David Levi comments: "We are delighted for the company to be able to conclude the TSP process. We exit the TSP on a far stronger financial footing than when we entered, thanks to the encouraging customer contracts and the fundraise we undertook in December.

----------

GreenRoc Mining PLC - UK and Greenland-focused mineral explorer - Announces the successful results of electrochemical battery test work using graphite from its Amitsoq graphite project in southern Greenland, and an update on its processing plant feasibility study. Chief Executive Stefan Bernstein says: "The outcome of this battery test programme is hugely pleasing. This is the first time that graphite material from our Amitsoq project has been tested for its performance within an assembled lithium ion battery cell. These results demonstrate that uncoated purified spherical graphite from Amitsoq performs very well as the active anode material in a battery cell, which is excellent news." Company says that the first and second work phases of the feasibility study are now complete. The next stages of the feasibility study include the design of both a pilot and full-scale processing plant, estimation of production rates, energy requirements and consumables, a full discounted cash flow model for the full-scale processing plant and integrating a risk model.

----------

Somero Enterprises Inc - Fort Myers, Florida-based laser-guided concrete levelling machinery company - Says following good trading and an excellent operational performance in fulfilling customer orders globally during the second half, it expects to report 2023 revenue of USD120.7 million, in line with previous guidance and market expectations. The 2023 revenue expectation reflects the positive impact of the S-22EZ relaunch at full production on trading and a resilient US non-residential construction market. A strong finish to the year was achieved despite ongoing headwinds in the US from concrete supply chain shortages, elevated interest rates and tightened bank lending. In 2024, expects the US market to remain strong, supported by customers reporting high levels of activity and healthy backlogs, continued growth in Europe and Australia, and multiple new product launches. Expects 2024 will be another highly profitable year with healthy cash generation, revenue comparable to 2023, and earnings before interest, tax, depreciation and amortisation that reflects modest incremental investment including the new Belgium service and training centre and the annualized impact of strategic resources added in 2023.

----------

Hummingbird Resources PLC - West Africa-focused and Birmingham, England-based gold producer, developer and explorer - Reports adjusted earnings before interest, tax, depreciation and amortisation in the fourth quarter ending December of USD0.2 million, resulting adjusted Ebitda for 2023 as a whole of USD34.5 million. Yanfolila produced 14,419 ounces of gold in the quarter, with a total of 83,965 oz in 2023, meeting production guidance of 80,000 to 90,000 oz. All in sustaining cost on gold produced at Yanfolila totalled USD1,701 per oz in the quarter, and USD1,361 per oz (in the year compared to USD1,782 per oz in 2022. This met the 2023 AISC guidance of under USD1,500/oz. Group production guidance for 2024 is 165,000 to 200,000 oz at an AISC below USD1,500, which is weighted towards the second half. Expects to spend USD5 million on exploration across both Yanfolila and Kouroussa.

----------

STV Group PLC - Glasgow-based television broadcaster and content producer - Increases its 25% equity stake in the high-end drama production company, Two Cities Television, to a majority holding of 51%. Explains the drama producer has secured revenue of GBP55 million over next 3 years across multiple series. Investment will help underpin Two Cities' growth and strengthen STV Studios' position as leading Nations & Regions producer. STV acquired a minority stake in Two Cities in January 2020, with an option to increase its initial stake to a majority position upon Two Cities becoming profitable.

----------

Botswana Diamonds PLC - Botswana and South Africa-focused diamond explorer - Announces that a consortium including BOD, which is acting as operator with a 30% stake, collectively known as Diamonds of Eswatini Pty Ltd, has been awarded a prospecting license over the diamondiferous Dokowayo kimberlites in Eswatini. Nil consideration was payable by BOD for its 30% interest. The License of just under 4,000 hectares is for an initial period of one year and renewable for a further year. The plan is to undertake an immediate, updated full desktop review and analysis of secondary sources. Following this, bulk sampling of the dumps and kimberlite stockpile is envisaged as the next step forward.

----------

Ariana Resources PLC - mineral exploration and development company with gold mining interests in Turkey, Cyprus and Kosovo - Updates on the 100% owned Asgard Metals Fund, highlighting some of its associated investments. Reports due diligence drilling programme on the Dokwe Gold project in Zimbabwe is ongoing, with the company increasing the current investment in Rockover Holdings to 2.1% by investing a further USD150,000. Highlights increased investment in Panther Metals to circa 5.5%, following an agreement to extend the consulting input of Asgard by a further year to the end of 2024. Notes Pallas Resources agrees an option and joint venture agreement with First Quantum Minerals, whilst securing BHP funding through their Xplor programme.

----------

Destiny Pharma PLC - Brighton, England-based biotechnology company - Announces positive data from a pivotal preclinical safety study of XF-73 Dermal, used for the treatment of antibiotic resistant skin infections associated with open wounds and broken skin. The product was well tolerated with no significant impact on any clinical or safety parameters and had no apparent negative impact on wound healing. Intends initially to progress XF-73 Dermal towards clinical evaluation for the treatment of Diabetic Foot Infections and serious burn wound infections. Further, changes its contract development manufacturing organisation for NTCD-M3 in order to strengthen manufacturing for clinical trial material and improve future commercial supply. These changes mean that the company now expect drug product for the next stage of clinical development to be available in the second half of 2024.

----------

Mobile Streams PLC - London-based mobile content provider - Completes the acquisition of all associated intellectual property for the print and digital operations of Estadio, and Capital Media Group has also transferred and recruited employees to work on the publication. Believes this provides a solid foundation for the relaunch and extension of the brand. Preparations for the launch of the Mexican betting business (in which MOS has a 25% direct shareholding) are well underway and the business is on track to launch early in the second quarter.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
22 Dec 2022 11:25

Destiny Pharma on track for commercial agreement for NTCD-M3 drug

(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.

Read more
7 Dec 2022 17:35

Destiny Pharma eyes potential billion dollar returns from Nasal asset

(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal infections.

Read more
7 Dec 2022 16:27

Destiny Pharma finalises plans for next study of its lead asset

(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.

Read more
15 Nov 2022 16:16

Destiny Pharma starts new drug study for its skin infection treatment

(Alliance News) - Destiny Pharma PLC on Tuesday said it had started a safety study to enable its XF-73 treatment to be labelled as an Investigational New Drug.

Read more
15 Nov 2022 12:53

Destiny Pharma starts new safety study of dermal formulation

(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.

Read more
8 Sep 2022 15:17

Destiny Pharma loss widens, pins hope on late stage clinical assets

(Alliance News) - Destiny Pharma PLC on Thursday reported a widened interim loss, as it progresses two key clinical assets.

Read more
7 Sep 2022 17:21

Destiny Pharma gets positive EMA feedback for gut bacteria treatment

(Alliance News) - Destiny Pharma PLC on Wednesday announced that it had received positive feedback from the European Medicine Agency on its NTCD-M3 phase 3 development plans.

Read more
7 Sep 2022 08:06

Destiny Pharma receives 'positive feedback' from EMA on NTCD-M3

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.

Read more
1 Sep 2022 15:59

UK earnings, trading statements calendar - next 7 days

Friday 2 September 
Ashmore Group PLCFull Year Results
Monday 5 September 
Belvoir Group PLCHalf Year Results
Dechra Pharmaceuticals PLCFull Year Results
Tuesday 6 September 
Accrol Group Holdings PLCFull Year Results
Alumasc Group PLCFull Year Results
Ashtead Group PLCQ1 Results
Capricorn Energy PLCHalf Year Results
Gamma Communications PLCHalf Year Results
Headlam Group PLCHalf Year Results
Inspired PLCHalf Year Results
IQE PLCHalf Year Results
Lords Group Trading PLCHalf Year Results
Luceco PLCHalf Year Results
Michelmersh Brick Holdings PLCHalf Year Results
Midwich Group PLCHalf Year Results
NCC Group PLCFull Year Results
PCI-PAL PLCFull Year Results
Pebble Group PLCHalf Year Results
Quixant PLCHalf Year Results
STV Group PLCHalf Year Results
WAG Payment Solutions PLCHalf Year Results
WANdisco PLCHalf Year Results
Wednesday 7 September 
Bakkavor Group PLCHalf Year Results
Barratt Developments PLCFull Year Results
Equals Group PLCHalf Year Results
M Winkworth PLCHalf Year Results
Malin Corp PLCHalf Year Results
Petropavlovsk PLCHalf Year Results
Somero Enterprises IncHalf Year Results
Tissue Regenix Group PLCHalf Year Results
WH Smith PLCTrading Statement
Thursday 8 September 
Arecor Therapeutics PLCHalf Year Results
Cairn Homes PLCHalf Year Results
Curtis Banks Group PLCHalf Year Results
Darktrace PLCFull Year Results
Destiny Pharma PLCHalf Year Results
Duke Royalty LtdFull Year Results
Emis Group PLCHalf Year Results
Energean PLCHalf Year Results
Funding Circle Holdings PLCHalf Year Results
Genus PLCFull Year Results
International Public Partnerships LtdHalf Year Results
Melrose Industries PLCHalf Year Results
Mpac Group PLCHalf Year Results
Oakley Capital Investments LtdHalf Year Results
Open Orphan PLCHalf Year Results
Restaurant Group PLCHalf Year Results
Safestore Holdings PLCQ3 Results
Severfield PLCFull Year Results
Shield Therapeutics PLCHalf Year Results
SourceBio International PLCHalf Year Results
Spire Healthcare Group PLCHalf Year Results
Sylvania Platinum LtdFull Year Results
Vistry Group PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
26 Jul 2022 22:16

TRADING UPDATES: De La Rue cancels contract; Apollon buys in Jamaica

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
19 Jul 2022 20:01

TRADING UPDATES: Capital backs outlook; Northcoders trades well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
12 Jul 2022 15:39

Destiny Pharma awarded Cystic Fibrosis Foundation project

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.

Read more
12 Jul 2022 12:07

IN BRIEF: Destiny Pharma receives undisclosed grant for MRSA study

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA.

Read more
7 Jul 2022 20:38

IN BRIEF: Destiny Pharma XF-73 shown to enhance activity of two drugs

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - New data on its XF-73 drug show that it can boost the effectiveness of current standard of care antibiotics when used in combinational therapy. The new in-vitro data stemmed from experiments by studies at the School of Dentistry, Cardiff University, for the potential for XF-based drugs to enhance the effectiveness of key antibacterial treatments. When combined with polymyxin B, a last resort antibacterial drug used to treat life-threatening lung bacterial infections, XF-73 enhanced polymyxin B potency against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by 4-fold, the research found.

Read more
5 Jul 2022 11:43

IN BRIEF: Destiny Pharma begins research on XF-73 for oral mucositis

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Starts new research programme in the US on oral mucositis, an inflammation of the mouth that is a common side effect of chemotherapy and radiotherapy. Firm tests its experimental drug candidate XF-73 as potential preventive medicine to ease suffering from oral mucositis. Explains that XF-73 has shown unique antimicrobial properties in phase 2 clinical trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.